By Foo Yun Chee and Maggie Fick BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of ...

Catalent Inc ( (CTLT)) has released its Q1 earnings. Here is a breakdown of the information Catalent Inc presented to its investors. Catalent Inc., a leading global contract development and ...

Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug ...

Reports Q1 revenue $ $1.02B , consensus $1.06B…Q1’25 Adjusted EBITDA of $125 million increased 11% as reported, or 10% in constant ...

The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief ...

And please do keep in touch. … European Union antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings’ ...

The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...

Ardena, a Belgium-based pharmaceutical contract manufacturer, will acquire Catalent’s facility in Somerset, New Jersey, ...

Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...

Catalent (NYSE: CTLT), a contract development and manufacturing organization (CDMO), reported results for Q1 of fiscal 2025 that missed analyst expectations. The ...